biotech

Hazmat

Lakeland Living Up to Production Promises

Lakeland Industries Inc. (NASDAQ: LAKE) gave an update Thursday on its business activity in the wake of the Ebola crisis. Globally the two top-selling protective suits for Lakeland are the ...
Read Full Story »
health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
Money background. Close-up.

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences Inc. (NASDAQ: GILD) reported its third-quarter results after the market close on Monday as $1.84 in earnings per share and $6.04 billion in revenue. That was against Thomson ...
Read Full Story »
biotech

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its third-quarter earnings after the U.S. markets close on Tuesday. Thomson Reuters has consensus estimates of $1.92 in earnings per shares ...
Read Full Story »
Pills

Amgen Posts 52-Week High, Beats It Again After Earnings

Drug maker Amgen Inc. (NASDAQ: AMGN) reported third-quarter 2014 results after markets closed Monday afternoon. The biotech company reported quarterly adjusted diluted earnings per share (EPS) of $2.30 and revenues ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Ebola Virus

New Ebola Fears in NYC Make Major Ebola Stock Waves (Updated)

Just when you thought the Ebola virus outbreak risk was dwindling down... Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all ...
Read Full Story »
DNA

Will Celgene Become the Next $100 Billion Biotech Stock?

Does Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech ...
Read Full Story »
biotech

Biogen Takes Breather on Earnings and MS Drug Sales

Biogen Idec Inc. (NASDAQ: BIIB) reported its third-quarter results before the market opened Wednesday as $3.80 in earnings per share and $2.5 billion in revenue. That was against Thomson Reuters ...
Read Full Story »
Stock Split Image

The Plan to Drive Amgen Shares Up Over 70%

Amgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that ...
Read Full Story »
biotech

Why Everyone Likes Illumina Again

Illumina Inc. (NASDAQ: ILMN) reported its earnings before the market opened Monday as $0.77 in earnings per share and $481 in revenue which beat out consensus estimates. On the heels ...
Read Full Story »
health care

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

There had been some brief hopes that the worst was over for struggling MannKind Corp. (NASDAQ: MNKD). It turns out that not all great FDA approvals end up being great ...
Read Full Story »
Ebola Virus

Ebola Stock Fallout Severe on Monday

Is the Ebola scare over in the United States? Probably not by a long shot. That being said, Ebola fears are subsiding on Monday as dozens of people came off ...
Read Full Story »
Merger

NewLink Scores Major Partners With Roche’s Genentech

NewLink Genetics Corp. (NASDAQ: NLNK) announced that it has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's ...
Read Full Story »
research

Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential

While Friday was a welcome relief for shell-shocked stock investors, much of the damage that has been inflicted since the start of the quarter is still weighing on some top ...
Read Full Story »